Across TCGA pan-cancer cohorts, RNU6ATAC19P RNA is linked to patient survival in 2 of 34 cancer types, making it the most broadly survival-associated RNU6ATAC19P data layer.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher RNU6ATAC19P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6ATAC19P expression acts as an unfavorable survival marker, although some lineages such as STAD show a favorable association.

ESCA and STAD are the cancer types where RNU6ATAC19P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Tertile	II,III,IV	0.269	0.530	.042	9	view →
STAD	OS	Tertile	II,III,IV	1.000	0.644	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RNU6ATAC19P tumor-vs-normal RNA expression · all RNU6ATAC19P data types